OBJECTIVE: To describe the incidence and clinical relevance of biochemical and objective responses to abiraterone acetate (AA) withdrawal (AAWD) in patients with castration-resistant prostate cancer (CRPC).
MATERIALS AND METHODS: Twenty-six patients with progressive CRPC treated with first-line docetaxel-based chemotherapy were administered with AA at the standard dose of 1000 mg/day in combination with prednisone until progression. The patients were regularly followed up during treatment and after AAWD.
RESULTS: Nineteen of the 26 patients discontinued AA because of progression. Three of the patients undergoing AAWD experienced a biochemical response, which was accompanied by a metabolic and radiological response as revealed by choline positron emission tomography in 2 cases.
CONCLUSION: Regardless of the underlying molecular bases, AAWD response does not occur rarely. It is sometimes long-lasting and accompanied by a metabolic and radiographic improvement. AAWD response should be taken into account when further therapeutic strategies are planned in patients with CRPC with progressive disease during abiraterone therapy.
Written by:
Caffo O, Palermo A, Veccia A, Maines F, Chierichetti F, Berruti A, Galligioni E. Are you the author?
Medical Oncology Department, Santa Chiara Hospital, Trento, Italy.
Reference: Urology. 2013 Aug 31. pii: S0090-4295(13)00894-7.
doi: 10.1016/j.urology.2013.07.029
PubMed Abstract
PMID: 24001702
UroToday.com mCRPC Treatment Section
